This training grant in its 25th year proposes a minimum of two years of postdoctoral training in Immunodermatology or Cutaneous Oncology for a full time career in Academic Dermatology in the Department of Dermatology of the University of Colorado at Denver and Health Sciences Center (UCDHSC). The scope of this training program has been increased to better prepare graduates for the collaborative research environment of the future including """"""""NIH Roadmap"""""""" proposals involving the interface of basic and clinical research. David Morris MD has been the PI of this grant for the past 5 years, and will continue to develop the collaborative interactions critical to this institutional training grant. An Executive Committee will supervise the management of training and recruitment of fellows. Since 1984,19 of 25 fellowship graduates have entered full time academic careers and 16 are currently retained in full time academic Dermatology. Five graduates are full time research faculty members of the Department of Dermatology at UCDHSC. The training faculty has extensive experiences in managing research teams and in training and mentoring research fellows. Training will prepare young investigators to participate in multi-disciplinary bench-to-bedside research projects in Cutaneous Oncology or Immunodermatology, the major interests in Dermatology at UCDHSC. Training in fundamental carcinogenesis, acquired and innate immunity, molecular biology and genetics, cell signaling, and cell death are available as foci for trainees. Some trainees will also include research training in outcomes-based medicine, dermatoepidemiology or translational research related to cancer and autoimmunity. M.D., M.D. /Ph.D or Ph.D candidates will be included with two trainees recruited each year. Four essentials of training are proposed: Individual research projects, formal coursework, seminars, and training in communications skills. Coursework will emphasize Immunology, Cancer, or Clinical Investigation, with additional training in Scientific Ethics, Career Development Skills, and Biostatistics. Trainees and their training supervisors will select research projects and build a course profile that complements the project. Training in communication skills will be supervised by Drs. Armstrong and Ansel.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Program Officer
Cibotti, Ricardo
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
Schools of Medicine
United States
Zip Code
Kogut, Igor; McCarthy, Sandra M; Pavlova, Maryna et al. (2018) High-efficiency RNA-based reprogramming of human primary fibroblasts. Nat Commun 9:745
Zhai, Z; Liu, W; Kaur, M et al. (2017) NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma. Oncogene 36:3820-3830
Shellman, Yiqun G; Lambert, Karoline A; Brauweiler, Anne et al. (2015) SASH1 Is Involved in an Autosomal Dominant Lentiginous Phenotype. J Invest Dermatol 135:3192-3194
Mukherjee, Nabanita; Reuland, Steven N; Lu, Yan et al. (2015) Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells. J Invest Dermatol 135:842-850
Reuland, Steven N; Smith, Shilo M; Bemis, Lynne T et al. (2013) MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD). J Invest Dermatol 133:1286-93
Reuland, Steven N; Goldstein, Nathaniel B; Partyka, Katie A et al. (2012) ABT-737 synergizes with Bortezomib to kill melanoma cells. Biol Open 1:92-100
Reuland, Steven N; Goldstein, Nathaniel B; Partyka, Katie A et al. (2011) The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53. PLoS One 6:e24294
Ellis, Lixia Z; Liu, Weimin; Luo, Yuchun et al. (2011) Green tea polyphenol epigallocatechin-3-gallate suppresses melanoma growth by inhibiting inflammasome and IL-1? secretion. Biochem Biophys Res Commun 414:551-6
Anwar, Adil; Norris, David A; Fujita, Mayumi (2011) Ubiquitin proteasomal pathway mediated degradation of p53 in melanoma. Arch Biochem Biophys 508:198-203
Okamoto, Miyako; Liu, Weimin; Luo, Yuchun et al. (2010) Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem 285:6477-88

Showing the most recent 10 out of 55 publications